Clinical Trial Update: AZA Combined With RCHOP in P53-mutated DLBCL. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating azacitidine in combination with the R-CHOP regimen for TP53-mutated diffuse large B-cell lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• R-CHOP regimen

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: DLBCL - Diffuse Large B Cell Lymphoma, TP53 | Phase 2 | Status: RECRUITING